Emalex Biosciences
Phase 3Developing a new class of drug for Tourette syndrome
Founded
2018
Focus
Small Molecules
About
Developing a new class of drug for Tourette syndrome
Funding History
2Total raised: $330M
Series B$250MBain Capital Life SciencesOct 15, 2021
Series A$80MParagon BiosciencesJun 15, 2018
Company Info
TypePrivate
Founded2018
LocationChicago, United States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile